Large-scale long-term follow-up study of japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma

American Journal of Gastroenterology

Volumn 107, Issue 2, 2012, Pages 253-261

  Kawamura, Yusuke ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Seko, Yuya ^a   Imai, Norihiro ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Ohmoto, Yuki ^a   Amakawa, Kazuhisa ^a   Tsuji, Hiroshi ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; THROMBOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84856736177     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.327     Document Type: Article

References (50)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50. (Pubitemid 29114292)
2. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-85. (Pubitemid 29488770)
3. Okuda K, Fujimoto I, Hanai A et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72. (Pubitemid 17143048)
4. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987; 4: 140-7.
5. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53. (Pubitemid 23193616)
6. Yamanaka N, Tanaka T, Tanaka W et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997; 79: 1509-15. (Pubitemid 27154780)
7. Koike Y, Shiratori Y, Sato S et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-23.
8. Yotsuyanagi H, Shintani Y, Moriya K et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis 2000; 181: 1920-8. (Pubitemid 30416153)
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
10. Williams R. Global changes in liver disease. Hepatology 2006; 44: 521-6.
11. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis . Gastroenterology 2008; 134: 1682-98. (Pubitemid 351615413)
12. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
13. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-10.
14. Watanabe S, Yaginuma R, Ikejima K et al. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-18.
15. Vega GL, Chandalia M, Szczepaniak LS et al. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007; 46: 716-22. (Pubitemid 47436117)
16. van der Poorten D, Milner KL, Hui J et al. Visceral fat a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.
17. Fan JG, Li F, Cai XB et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22 : 1086-91. (Pubitemid 47019857)
18. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
19. Stern SE, Williams K, Ferrannini E et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54: 333-9.
20. Muniyappa R, Lee S, Chen H et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: E15-26.
21. Adams LA, Feldstein A, Lindor KD et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39: 909-14. (Pubitemid 38428928)
22. Tann é F, Gagnadoux F, Chazouill è res O et al. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290-6.
23. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E et al. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 2008; 133: 92-9.
24. Arase Y, Suzuki F, Ikeda K et al. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 2009; 44: 1064-70.
25. Adams LA, Lymp JF, St Sauver J et al. Th e natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21. (Pubitemid 41002048)
26. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-8. (Pubitemid 19164370)
27. Powell EE, Cooksley WG, Hanson R et al. Th e natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80. (Pubitemid 20075105)
28. Teli MR, James OF, Burt AD et al. Th e natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
29. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9. (Pubitemid 29258890)
30. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5. (Pubitemid 38561456)
31. Evans CD, Oien KA, MacSween RN et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002; 55: 689-92. (Pubitemid 34970092)
32. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. (Pubitemid 36919874)
33. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-C á rdenas E et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350-7.
34. Harrison SA, Oliver D, Arnold HL et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
35. Lonardo A, Bellini M, Tartoni P et al. The bright liver syndrome. Prevalence and determinants of a " bright " liver echopattern. Ital J Gastroenterol Hepatol 1997; 29: 351-6. (Pubitemid 28059513)
36. Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87. (Pubitemid 46924065)
37. Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
38. Fleming TR, Harrington DP, O ' Brien PC. Designs for group sequential tests. Control Clin Trials 1984; 5: 348-61. (Pubitemid 15175662)
39. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74. (Pubitemid 29420675)
40. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
41. Ratziu V, Bonyhay L, Di Martino V et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93. (Pubitemid 34966903)
42. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-61.
43. Ekstedt M, Franz é n LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 : 865-73. (Pubitemid 46489550)
44. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
45. Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
46. Amarapurkar DN, Hashimoto E, Lesmana LA et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-93. (Pubitemid 46911047)
47. Kojima S, Watanabe N, Numata M et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-61. (Pubitemid 37455782)
48. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143 : 722-8.
49. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 : 1820-32.
50. Ruhl CE, Everhart JE. Determinants of the association of overweight wiThelevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-9. (Pubitemid 36055340)